Journal of Clinical Endocrinology & Metabolism, Vol 44, 32-38, Copyright © 1977 by Endocrine Society

ARTICLES

Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA

A Ortiz, M Hirol, FZ Stanczyk, U Goebelsmann and DR Mishell

A sensitive radioimmunoassay measuring serum medroxyprogesterone acetate (MPA) has been developed in order to measure and correlate serum MPA concentrations and ovarian function in women following im administration of deop-MPA (DMPA), employing goat anti-MPA-3-(O- carboxymethyl) oxime-bovine serum albumin and MPA-3-(O-carboxymethyl) imino-125I-iodohistamine. In the 3 women studied, im injection of 150 mg of DMPA yielded brief initial serum MPA concentrations ranging from 1.5 to 3 ng/ml for a few days. Serum MPA concentrations gradually declined and remained relatively constant at about 1 ng/ml for 2 to 3 months, declined gradually thereafter reaching 0.2 ng/ml during the 6th month and became undetectable (less than 0.02 ng/ml) about 7-1/2 to 9 months following administration. Serum estradiol remained at early to midfollicular phase levels for 4 to 6 months after DMPA injection and rose to preovulatory levels when serum MPA levels fell below 0.5 to 0.25 ng/ml. Ovulation, however, as evidenced by serum progesterone concentrations did not occur, apparently due to suppression of the LH peak by positive feedback inhibition. Prolonged inhibition of cyclic ovarian function following DMPA injection is caused by slow MPA absorption and persists until serum MPA levels have decreased below 0.1 ng/ml or become undetectable about 7 to 9 months after DMPA administration.

This article has been cited by other articles:

				Z. HAREL Dysmenorrhea in Adolescents Ann. N.Y. Acad. Sci., June 1, 2008; 1135(1): 185 - 195. [Abstract] [Full Text] [PDF]

				A. E. Bonny, J. Ziegler, R. Harvey, S. M. Debanne, M. Secic, and B. A. Cromer Weight Gain in Obese and Nonobese Adolescent Girls Initiating Depot Medroxyprogesterone, Oral Contraceptive Pills, or No Hormonal Contraceptive Method Arch Pediatr Adolesc Med, January 1, 2006; 160(1): 40 - 45. [Abstract] [Full Text] [PDF]

				L. P. Ly, P. Y. Liu, and D. J. Handelsman Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens Hum. Reprod., June 1, 2005; 20(6): 1733 - 1740. [Abstract] [Full Text] [PDF]

				K. Pazol, M. E. Wilson, and K. Wallen Medroxyprogesterone Acetate Antagonizes the Effects of Estrogen Treatment on Social and Sexual Behavior in Female Macaques J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2998 - 3006. [Abstract] [Full Text] [PDF]

				D. Zhao, D. I. Lebovic, and R. N. Taylor Long-Term Progestin Treatment Inhibits RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) Gene Expression in Human Endometrial Stromal Cells J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2514 - 2519. [Abstract] [Full Text] [PDF]

				D. SCHOLES, A. Z. LACROIX, S. M. OTT, L. E. ICHIKAWA, and W. E. BARLOW Bone Mineral Density in Women Using Depot Medroxyprogesterone Acetate for Contraception Obstet. Gynecol., February 1, 1999; 93(2): 233 - 238. [Abstract] [Full Text] [PDF]